Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04940286 · ClinicalTrials.gov registry record · Phase 2

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

A Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma and Stage IIA Pancreatic Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
13
Enrollment target
1
Study location

NCT04940286 is a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma and Stage IIA Pancreatic Cancer AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants, below the 49-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04940286, a Phase 2 study of Borderline Resectable Pancreatic Adenocarcinoma and Stage IIA Pancreatic Cancer AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the effects of gemcitabine, nab-paclitaxel, durvalumab, and oleclumab in treating patients with primary pancreatic cancer that may be able to be removed by surgery (resectable/borderline resectable). Chemotherapy drugs, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and oleclumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving gemcitabine, nab-paclitaxel, durvalumab, and oleclumab may help control the disease in patients with resectable/borderline resectable primary pancreatic cancer.

Conditions Studied

Borderline Resectable Pancreatic Adenocarcinoma Stage IIA Pancreatic Cancer AJCC v8 Resectable Pancreatic Adenocarcinoma Stage IIB Pancreatic Cancer AJCC v8 Stage IA Pancreatic Cancer AJCC v8 Stage IB Pancreatic Cancer AJCC v8

Interventions

  • BIOLOGICAL Durvalumab
  • DRUG Gemcitabine
  • DRUG Nab-paclitaxel
  • BIOLOGICAL Oleclumab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2021-09-28
Est. Completion 2027-10-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04940286

The ClinicalTrials.gov registry entry for NCT04940286 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 7 other Borderline Resectable Pancreatic Adenocarcinoma trials with a reported enrollment target (73% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Borderline Resectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Durvalumab is the first listed.

NCT04940286 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04940286 about?

NCT04940286 is a clinical study titled "Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer". This phase II trial studies the effects of gemcitabine, nab-paclitaxel, durvalumab, and oleclumab in treating patients with primary pancreatic cancer that may be able to be removed by surgery (resectable/borderline resectable). Chemotherapy drugs, such as gemcitabine and nab-paclitaxel, work in diff...

What is the current status of trial NCT04940286?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2021-09-28. Estimated completion is 2027-10-30.

What conditions does trial NCT04940286 study?

This clinical trial studies the following conditions: Borderline Resectable Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer AJCC v8, Resectable Pancreatic Adenocarcinoma, Stage IIB Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8.

What interventions are being tested in trial NCT04940286?

The interventions under investigation include: Durvalumab (BIOLOGICAL), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Oleclumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04940286?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04940286 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Borderline Resectable Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Borderline Resectable Pancreatic Adenocarcinoma

All registered trials for this condition

Stage IIA Pancreatic Cancer AJCC v8

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.